Morgan Stanley upgraded shares of Novartis AG (NYSE:NVS) from an underweight rating to an overweight rating in a research report sent to investors on Wednesday, MarketBeat Ratings reports.

Several other equities research analysts have also recently weighed in on NVS. UBS AG reiterated a neutral rating on shares of Novartis AG in a report on Tuesday, May 30th. J P Morgan Chase & Co reiterated a neutral rating on shares of Novartis AG in a report on Thursday, June 8th. Cowen and Company reiterated a hold rating on shares of Novartis AG in a report on Tuesday, July 18th. TheStreet upgraded Novartis AG from a c+ rating to a b rating in a report on Friday, June 2nd. Finally, Vetr cut Novartis AG from a strong-buy rating to a buy rating and set a $78.32 price objective for the company. in a report on Thursday, April 6th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $81.71.

Shares of Novartis AG (NVS) opened at 84.75 on Wednesday. The company has a market capitalization of $198.56 billion, a P/E ratio of 30.94 and a beta of 0.73. The firm has a 50-day moving average price of $83.39 and a 200-day moving average price of $77.82. Novartis AG has a one year low of $66.93 and a one year high of $86.90.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same quarter last year, the business posted $1.23 EPS. The business’s revenue was down 1.8% on a year-over-year basis. Equities analysts forecast that Novartis AG will post $4.78 earnings per share for the current year.

WARNING: “Novartis AG (NVS) Raised to “Overweight” at Morgan Stanley” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/novartis-ag-nvs-raised-to-overweight-at-morgan-stanley/1462617.html.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of Novartis AG stock in a transaction that occurred on Wednesday, July 5th. The stock was bought at an average price of $15.00 per share, with a total value of $4,000,005.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 0.01% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Howe & Rusling Inc. raised its position in Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares during the period. City Holding Co. raised its position in Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares during the period. TCI Wealth Advisors Inc. raised its position in Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares during the period. Archford Capital Strategies LLC raised its position in Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares during the period. Finally, Kernodle & Katon Asset Management Group LLC raised its position in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares during the period. 11.30% of the stock is owned by institutional investors.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.